| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3976945 | Brachytherapy | 2015 | 6 Pages |
Abstract
BA leads to a higher target dose, similar dose to organs at risk, but potentially with lower target coverage compared with SABR. Further work is needed to determine ideal suitability for mono vs. combination therapy with this approach.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Daniel Pennington, Sang June Park, Narine Abgaryan, Robyn Banerjee, Percy P. Lee, Christopher Loh, Edward Lee, D. Jeffrey Demanes, Mitchell Kamrava,